Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer

Journal of the National Cancer Institute

Volumn 87, Issue 10, 1995, Pages 746-750

  Osborne, C Kent ^a   Coronado heinsohn, Ester B ^a   Hilsenbeck, Susan G ^a   Mccue, Bryant L ^a   Wakeling, Alan E ^b   Mccleland, Richard A ^c   Manning, David L ^c   Nicholson, Robert I ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ASTRAZENECA   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; ESTROGEN THERAPY; FEMALE; GROWTH INHIBITION; HUMAN; NUDE MOUSE;

ANALYSIS OF VARIANCE; ANIMAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPARATIVE STUDY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN;

EID: 0029075872     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/87.10.746     Document Type: Article

References (23)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women. Early Breast Cancer Trialists’ Collaborative Group [see comment citations in Medline]. Lancet 339:1-15, 71-85, 1992
2. Encamacion CA, Ciocca DR, McGuire WL, et al: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-246, 1993
3. Osborne CK, Coronado E, Allred DC, et al: Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxi- fen [see comment citation in Medline]. J Natl Cancer Inst 83:1477-1482, 1991
4. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
5. Pritchard KI, Thomson DB, Myers RE, et al: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787-796, 1980
6. Hoogstraten B, Gad-el-Mawla N, Maloney TR, et al: Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54:2248-2256, 1984
7. Osborne CK, Jarman M, McCague R, et al: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95, 1994
8. Wakeling AE, Bowler J: Novel antioestrogens without partial agonist activity. J Steroid Biochem 31:645-653, 1988
9. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873, 1991
10. Wakeling AE: Steroidal pure antiestrogens. In Regulatory Mechanisms in Breast Cancer (Lippman M, Dickson R, eds). Boston: Kluwer AcadPubl, 1991, pp 239-257
11. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989
12. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590, 1985
13. Manning DL, McClelland RA, Gee JM, et al: The role of four oestrogen-responsive genes, pLIVl, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in pri mary breast cancer. Eur J Cancer 29A:1462- 1468, 1993
14. Brunner N, Frandsen TL, Holst-Hansen C, et al: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182, 780. Cancer Res 53:3229-3232, 1993
15. Lykkesfeldt AE, Sorensen EK: Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell lines MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31:131-138, 1992
16. Parker MG: Action of pure antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26:131 -137, 1993
17. Wiebe VJ, Osborne CK, Fuqua SA, et al: Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 14:173-188, 1993
18. DeFriend DJ, Howell A, Nicholson RI, et al: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408-414, 1994
19. DeFriend DJ, Blarney RW, Robertson JF, et al: Response to the pure antiestrogen ICI 182780 after tamoxifen failure in advanced breast cancer. Breast Cancer Res Treat 17:136, 1993
20. Gibson MK, Nemmers LA, Beckman WC Jr, et al: The mechanism of ICI 164, 384 an- tiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129:2000-2010, 1991
21. Love RR, Mazess RB, Barden HW, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comment citation in Medline]. N Engl J Med 326:852-856, 1992
22. Love RR, Newcombe PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer [see comment citation in Medline]. J Natl Cancer Inst 82:1327-1332, 1990
23. Fomander T, Hellstrom AC, Moberger B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85:1850-1855, 1993